CF welcomes Ioannis Katsoulis as director of life sciences
Ioannis Katsoulis has joined CF as director of life sciences, bringing over 12 years of experience in global market access, pricing, and health policy research to the firm. Speaking on his appointment, Katsoulis said he was “energised to join CF and help expand its market access capabilities”.
He added, “Looking forward to partnering with clients to deliver impactful, data-driven solutions that accelerate access and improve patient outcomes."
CF is a consultancy specialising in the health and healthcare space. The firms works with leaders and frontline teams to improve health, transform healthcare, drive adoption of innovation and create value through investment, from offices in London, Riyadh and Dubai. It serves clients in the UK and across Europe and the Middle East.
Katsoulis’ expertise will open new doors around the world, having presented at opinion leader engagements across major global markets, with a focus on the EU4 markets, the UK, US, China and Japan. With a strong track record of delivering strategic insights across top pharmaceutical and biotech companies, he has partnered with cross-functional teams throughout his career to optimise the value proposition of therapies by demonstration of benefits for patients and healthcare systems.
Real-world knowledge
Hannah Farrar, CEO of CF, noted, "Ioannis’s appointment underscores our commitment to deepening our life sciences expertise and expanding our market access capabilities. His extensive experience in leveraging real-world evidence to inform healthcare decision-making aligns perfectly with our mission to drive meaningful impact across the healthcare sector. We’re building a team that can deliver transformative outcomes for our clients, and Ioannis will make a great addition to that vision."
Most recently, Katsoulis served as Associate Principal at IQVIA, leading value communications and pricing engagements across therapy areas. Prior to IQVIA, he held roles of increasing responsibility at different consultancies including Evidera and ICON, where he engaged in health technology assessment (HTA), market access and pricing for medicines across their lifecycle. His work has informed evidence generation plans, global value dossiers, launch readiness, and global market access and pricing strategy.
Ben Richardson, managing partner of life sciences for CF, added, “Ioannis has a strong background in the market access field... His appointment reflects our commitment to bringing world-class talent to CF as we continue to expand our life sciences capabilities. His experience as a strategic advisor to global pharmaceutical and biotech companies, combined with his expertise in real-world evidence and health technology assessment, will significantly strengthen our ability to leverage our unrivalled access to health data in the UK making it relevant for life sciences companies in the UK and across Europe.”
